Where does XII Medical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), XII Medical, Inc. ranks #30,643 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does XII Medical, Inc. hold?

XII Medical, Inc. holds 9 US utility patents granted between 2022 and 2024, spanning 6 technology areas.

What is XII Medical, Inc.'s Innovation Score?

XII Medical, Inc. has an Innovation Score of 47.8 out of 100 (top 18% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is XII Medical, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for XII Medical, Inc..

What does claim depth mean for XII Medical, Inc.'s patents?

XII Medical, Inc.'s patents average 18.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the XII Medical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

XII Medical, Inc.

Q: What technology areas does XII Medical, Inc. focus on?

XII Medical, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 9 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, XII ranks #30,643 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.

#30,643
of 49,997 US assignees by volume: Top 18%
by Innovation Score (47.8/100): 18.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R30643 · US Corporation #30,643 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 9 grants
MID-PACK #30,643/49,997
PHOTO-FINISH Xaptum
CPC-NARROW A61N · 6 areas
INNOV-PAR 47.8/100
CLAIMS-RICH 18.7 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2024 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Xaptum, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
XII Medical · this assignee

48
3D Lighting… · lowest

7

What this shows XII's Innovation Score is 47.8/100 (top 18% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where XII's grants concentrate

XII Medical, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2022 (5 grants) versus a trough of 1 in 2023. By volume, XII sits between XIA MEN Mint Furniture Co., Ltd. and Xentris Wireless, LLC.

XII's three-year grant acceleration

XII Medical, Inc. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

XIA MEN Mint Furn…

9
Xiamen Honor Indu…

9
Xiamen Sigmastar…

9
Xiangshan Gemfan…

9
Xslent Energy

9
Xtend AI

9
Xaptum

9
Xentris Wireless

9
XII Medical ◀

9

What this shows XII holds 9 patents at rank #30,609, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near XII

By rank, the assignees closest to #30,609 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in XII's primary technology class.

XII's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 18% higher than 82% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

XII Medical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	5	55.6%
2023	1	11.1%
2024	3	33.3%

Which technologies does XII Medical, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 9

A61B - DIAGNOSIS; SURGERY; Identification 6

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 6

G06V - Image OR Video Recognition OR Understanding 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

G06T - Image Data Processing OR Generation, IN General 4

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#30,643

of 49,997 tracked assignees

Innovation Score

47.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

XII Medical, Inc.'s patent record in context - here's where to go next.

XII Medical, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #30,643 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare XII Medical, Inc. against XIA MEN Mint Furniture Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.